Update on the Antimicrobial Management of Foot Infections in Patients With Diabetes

IN BRIEF Foot infections are common problems in patients with diabetes and can lead to devastating complications and long-term morbidity. Although these infections invariably start in superficial soft tissues, they can involve deeper structures, including bone. Complications may include necrotizing fasciitis, soft tissue gangrene, septic arthritis, and osteomyelitis. This article reviews the factors involved in appropriate antibiotic selection and describes antimicrobial agents included in recently updated treatment guidelines from the Infectious Diseases Society of America.

[1]  A. Glaros,et al.  Clinical efficacy, tolerability, and cost savings associated with the use of open-label metronidazole plus ceftriaxone once daily compared with ticarcillin/clavulanate every 6 hours as empiric treatment for diabetic lower-extremity infections in older males. , 2004, The American journal of geriatric pharmacotherapy.

[2]  R. Raz,et al.  Risk Factors for the Development of Extended-Spectrum Beta-Lactamase-Producing Bacteria in Nonhospitalized Patients , 2004, European Journal of Clinical Microbiology and Infectious Diseases.

[3]  D. Levine,et al.  Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  A. Boulton,et al.  Methicillin-Resistant Staphylococcus aureus in Diabetic Foot Infections , 2010, Drugs.

[5]  H. Boucher,et al.  Current concepts in antimicrobial therapy against select gram-positive organisms: methicillin-resistant Staphylococcus aureus, penicillin-resistant pneumococci, and vancomycin-resistant enterococci. , 2011, Mayo Clinic proceedings.

[6]  Benjamin A Lipsky,et al.  Outpatient management of uncomplicated lower-extremity infections in diabetic patients. , 1990, Archives of internal medicine.

[7]  L. Harkless,et al.  An open-label, randomized study comparing efficacy and safety of intravenous piperacillin/tazobactam and ampicillin/sulbactam for infected diabetic foot ulcers. , 2005, Surgical infections.

[8]  S. Choi,et al.  Risk factors for the acquisition of carbapenem-resistant Klebsiella pneumoniae among hospitalized patients. , 2005, Microbial drug resistance.

[9]  C. Gentry,et al.  Analysis of Linezolid‐Associated Hematologic Toxicities in a Large Veterans Affairs Medical Center , 2010, Pharmacotherapy.

[10]  K. To,et al.  Effect of antibiotics on the bacterial load of meticillin-resistant Staphylococcus aureus colonisation in anterior nares. , 2008, The Journal of hospital infection.

[11]  Benjamin A Lipsky,et al.  Treating diabetic foot infections with sequential intravenous to oral moxifloxacin compared with piperacillin-tazobactam/amoxicillin-clavulanate. , 2007, The Journal of antimicrobial chemotherapy.

[12]  Sara E Cosgrove,et al.  Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  B. Allard,et al.  Wound Chronicity, Inpatient Care, and Chronic Kidney Disease Predispose to MRSA Infection in Diabetic Foot Ulcers , 2009, Diabetes Care.

[14]  J. Karlowsky,et al.  Comparative Review of the Carbapenems , 2012, Drugs.

[15]  K. Itani,et al.  The role of diabetes mellitus in the treatment of skin and skin structure infections caused by methicillin-resistant Staphylococcus aureus: results from three randomized controlled trials. , 2011, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[16]  D. Armstrong,et al.  Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial , 2005, The Lancet.

[17]  D. Talan,et al.  Once-daily, high-dose levofloxacin versus ticarcillin-clavulanate alone or followed by amoxicillin-clavulanate for complicated skin and skin-structure infections: a randomized, open-label trial. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  P. Gillman,et al.  Serotonin toxicity associated with the use of linezolid: a review of postmarketing data. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  E. Tschernko,et al.  Impaired Target Site Penetration of Vancomycin in Diabetic Patients following Cardiac Surgery , 2006, Antimicrobial Agents and Chemotherapy.

[20]  J. Morris,et al.  Risk Factors for Colonization with Extended-Spectrum β-Lactamase–producing Bacteria and Intensive Care Unit Admission , 2007, Emerging infectious diseases.

[21]  I. Kassis,et al.  Carbapenem Resistance Among Klebsiella pneumoniae Isolates Risk Factors, Molecular Characteristics, and Susceptibility Patterns , 2009, Infection Control & Hospital Epidemiology.

[22]  K. Carroll,et al.  Failure of clindamycin treatment of methicillin-resistant Staphylococcus aureus expressing inducible clindamycin resistance in vitro. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  F. Tenover,et al.  Characterization of Nasal and Blood Culture Isolates of Methicillin-Resistant Staphylococcus aureus from Patients in United States Hospitals , 2011, Antimicrobial Agents and Chemotherapy.

[24]  D. Armstrong,et al.  Executive summary: 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  T. File,et al.  Meropenem versus imipenem-cilastatin for the treatment of hospitalized patients with complicated skin and skin structure infections: results of a multicenter, randomized, double-blind comparative study. , 2005, Surgical infections.

[26]  D. Snydman,et al.  Update on resistance of Bacteroides fragilis group and related species with special attention to carbapenems 2006-2009. , 2011, Anaerobe.

[27]  D. Hinthorn,et al.  The cephalosporins. , 1985, Disease-a-month : DM.

[28]  Y. Yazdanpanah,et al.  Culture of percutaneous bone biopsy specimens for diagnosis of diabetic foot osteomyelitis: concordance with ulcer swab cultures. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  M. Alary,et al.  Fluoroquinolones and Risk for Methicillin-Resistant Staphylococcus aureus, Canada , 2006, Emerging infectious diseases.

[30]  L. Baddour,et al.  Antimicrobial resistance trends of Escherichia coli bloodstream isolates: a population-based study, 1998-2007. , 2008, The Journal of antimicrobial chemotherapy.

[31]  M. Synnestvedt,et al.  Imipenem Resistance in Pseudomonas aeruginosa Emergence, Epidemiology, and Impact on Clinical and Economic Outcomes , 2010, Infection Control & Hospital Epidemiology.

[32]  Anthony D. Harris,et al.  Risk Factors for Recovery of Ampicillin-Sulbactam-Resistant Escherichia coli in Hospitalized Patients , 2000, Antimicrobial Agents and Chemotherapy.

[33]  C. Natanson,et al.  Excess deaths associated with tigecycline after approval based on noninferiority trials. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[34]  D. Nathwani,et al.  A randomized trial of the efficacy and safety of sequential intravenous/oral moxifloxacin monotherapy versus intravenous piperacillin/tazobactam followed by oral amoxicillin/clavulanate for complicated skin and skin structure infections , 2011, The Journal of antimicrobial chemotherapy.

[35]  G. Gill,et al.  Methicillin-resistant Staphylococcus aureus (MRSA) isolation from diabetic foot ulcers correlates with nasal MRSA carriage. , 2007, Diabetes research and clinical practice.

[36]  Donald R. Miller,et al.  A classification of diabetic foot infections using ICD-9-CM codes: application to a large computerized medical database , 2010, BMC health services research.

[37]  D. G. Armstrong,et al.  Wound Microbiology and Associated Approaches to Wound Management , 2001, Clinical Microbiology Reviews.

[38]  Y. Taşova,et al.  Piperacillin/tazobactam versus imipenem/cilastatin for severe diabetic foot infections: a prospective, randomized clinical trial in a university hospital. , 2010, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[39]  Benjamin A Lipsky,et al.  Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections. , 2005, The Journal of antimicrobial chemotherapy.